Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37,988 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, Zhuang W, Zhao Y, Zhou M, Zhang W, Zhang Y, Wan Y, Li W, Song W, Wang ZM, Li B, Xia M, Yang Y, Fang W, Huang Y, Zhang L. Zhao Y, et al. Among authors: chen j, chen g. EClinicalMedicine. 2023 Aug 3;62:102106. doi: 10.1016/j.eclinm.2023.102106. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37593227 Free PMC article.
Validation of different personalized risk models of chemotherapy-induced nausea and vomiting: results of a randomized, double-blind, phase III trial of fosaprepitant for cancer patients treated with high-dose cisplatin.
Zhao Y, Zhao B, Chen G, Chen Y, Liao Z, Zhang H, Feng W, Li Y, Weng H, Li W, Zhou Y, Ren B, Lu Y, Chen J, Liu Z, Su Z, Wang W, Zhang L. Zhao Y, et al. Among authors: chen j, chen g, chen y. Cancer Commun (Lond). 2023 Feb;43(2):246-256. doi: 10.1002/cac2.12397. Epub 2022 Dec 22. Cancer Commun (Lond). 2023. PMID: 36545810 Free PMC article. Clinical Trial.
Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC.
Sun D, Liu J, Zhou H, Shi M, Sun J, Zhao S, Chen G, Zhang Y, Zhou T, Ma Y, Zhao Y, Fang W, Zhao H, Huang Y, Yang Y, Zhang L. Sun D, et al. Among authors: chen g. J Thorac Oncol. 2023 Jul;18(7):869-881. doi: 10.1016/j.jtho.2023.03.012. Epub 2023 Mar 21. J Thorac Oncol. 2023. PMID: 36948245 Free article. Clinical Trial.
QL1706 (anti-PD-1 IgG4/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study.
Huang Y, Yang Y, Zhao Y, Zhao H, Zhou N, Zhang Y, Chen L, Zhou T, Chen G, Wu T, Lu L, Xue S, Kang X, Zhang L, Fang W. Huang Y, et al. Among authors: chen l, chen g. Signal Transduct Target Ther. 2024 Jan 29;9(1):23. doi: 10.1038/s41392-023-01731-x. Signal Transduct Target Ther. 2024. PMID: 38282003 Free PMC article. Clinical Trial.
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial.
Zhao ZR, Liu SL, Zhou T, Chen G, Long H, Su XD, Zhang X, Fu JH, Lin P, Zhang LJ, Rong TH, Wu JD, Li ZC, Su HL, Chen JY, Yang YP, Lin YB, Xi M, Yang H. Zhao ZR, et al. Among authors: chen jy, chen g. Lancet Respir Med. 2024 Dec;12(12):988-996. doi: 10.1016/S2213-2600(24)00215-7. Epub 2024 Sep 18. Lancet Respir Med. 2024. PMID: 39305910 Clinical Trial.
Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy.
Sun T, Huang S, Jiang Y, Yuan H, Wu J, Liu C, Zhang X, Tang Y, Ben X, Tang J, Zhou H, Zhang D, Xie L, Chen G, Zhao Y, Wang S, Xu H, Qiao G. Sun T, et al. Among authors: chen g. Front Bioeng Biotechnol. 2022 Oct 6;10:1010672. doi: 10.3389/fbioe.2022.1010672. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36277407 Free PMC article.
Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy with Helical TomoTherapy Versus Conventional Radiation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Receiving Concurrent Chemotherapy: A Multicenter, Randomized Phase 3 Trial.
Zhang Q, Fan S, Xu X, Du S, Zhu G, Jiang C, Xia SA, Li Q, Wang Q, Qian D, Zhang M, Xiao H, Chen G, Zeng Z, He J. Zhang Q, et al. Among authors: chen g. Int J Radiat Oncol Biol Phys. 2024 Oct 1;120(2):422-431. doi: 10.1016/j.ijrobp.2024.03.030. Epub 2024 Apr 15. Int J Radiat Oncol Biol Phys. 2024. PMID: 38631536 Free article. Clinical Trial.
37,988 results
You have reached the last available page of results. Please see the User Guide for more information.